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Antiplatelets are medicines that stop cells in the blood (platelets) from sticking together and forming a clot, 
which may lead to a heart attack or stroke. Furthermore, the use of antiplatelet after percutaneous coronary 
intervention is one of the challenge encountered by the clinicians or hospital staff because it has to be 
calculated between the risk-benefit ratio. This study aims to evaluate the use of dual antiplatelet therapy in 
patients undergoing percutaneous coronary intervention. A retrospective study was used and data were 
obtained from patient records. The data obtained were analysed to know the relationship between age, 
gender, and type of drug combination associated with ischemic events. The patient demographics were 
analysed descriptively, and the comparison between age and sex group related to ischemic events was 
analysed using chi-square analysis. There was no statistical difference in ischemic events between age and 
sex group. The study reported that the most commonly used DAPT profile was the combination of Aspirin 
100 mg - Clopidogrel 75 mg (38%) and Aspirin 100 mg - Ticagrelor 90 mg (28%). The profile of ischemic 
events in patients using the aspirin-clopidogrel combination was lower than that of the aspirin-ticagrelor 
combination. 
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BACKGROUND 
The treatments used for patients with 
CHD are anti-ischemic, antithrombin / 
anticoagulant, antiplatelet, thrombolytic / 
fibrinolytic and additional drugs, such as ACE-
inhibitors. In addition to the conventional 
handling of some drugs, invasive procedure was 
also performed in CHD handling. Percutaneous 
Coronary Intervention (PCI) can be used as a 
premier revascularization therapy in some 
patients. Many experts have used this method 
because various studies have proven that PCI is 
more effective than thrombolytic drugs in 
relieving blocked blood flow or successful 
revascularization. The success rate also attained 
95%. (Yahya, Fauzi. 2010; MOH, 2006). In 
addition, a study involving a total of 4030 (3.1%) 
CHD patients with total occlusion that performed 
PCI had a successful treatment rate of 
61.3%. (Hannan et al, 2016). In Indonesia, PCI 
has been integrated into the national health 
insurance system. 
Patients that have 
undergone percutaneous coranary 
intervention (PCI) are advice to use dual 
antiplatelet therapy (aspirin and platelet 
adenosine diphosphate [ADP] receptor 
antagonists to minimize complications (Richard 
A. Lange, and L. David Hillis, 2013). According 
to the European Society of Cardiology, which 
focuses on Dual Anti-Platelet Therapy, estimates 
the number of patients in need of dual antiplatelet 
therapy (DAPT), which is a combination of 
aspirin and P2Y12 platelet receptor oral 
inhibitors for adenosine 5'-diphosphate (ADP) 
that is quite large and has increased over time in 
the Europe. Based on the population estimates 
from 2015 in a region there are 1,400,000 and 
2,200,000 patients per year that have indications 
for DAPT after coronary intervention. 
(Valgimigli M et al, 2017) 
The use of DAPT in post PCI patients is 
associated with a reduced risk 
of atherothrombotic events , which includes 
stent thrombosis and myocardial 
infarction. (Piccolo and Windecker, 
2016). Other studies have also shown that DAPT 
is the treatment of choice for post-PCI patients 
with stable coronary artery disease. Long-term 
use of DAPT (12 months) is beneficial for 
reducing serious cardiovascular events, 
compared with the combination of aspirin and 
placebo in patients that have ACS with non-ST 
segment elevation. (Miyazaki, Yosuke et 
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al, 2017). Furthermore, current evidence shows 
that DAPT reduces the risk of stent thrombosis 
across the spectrum, from acute to chronic 
events. However, treatment with DAPT for 1 
year after PCI has the advantage of reducing the 
recurrence rate of attacks, which is associated 
with a mortality rate of 15%. However, since 
advanced antiplatelet therapy is associated with 
an increased risk of bleeding, this risk must be 
considered for the potential benefit. (Valgimigli 
M et al , 2017). 
The study aims to evaluate the use of 
dual antiplatelet therapy in patients undergone 
percutaneous coronary intervention (PCI).  
 
METHODS 
The observational study design was 
used in patients after percutaneous coronary 
intervention. Patient medical records was 
obtained for data collection,  demographic, 
medical, and medication history. The population 
consists of post-PCI patients in a public hospital 
in Surabaya . The sample was enrolled in order 
to meets inclusion and exclusion criteria. The 
inclusion criteria were all post PCI patients with 
coronary heart disease using dual antiplatelet 
therapy (DAPT) while the exclusion criteria 
were all post PCI patients that had triple 
antiplatelet therapy. The data obtained from the 
results of the study were analysed 
descriptively. PCI with DES (Drug eluting stent) 
was used in this research. The data was presented 
in the form of narrative descriptions, tables and 
diagrams. The patient's progress is measured by 
ischemic events, which are described as recurrent 




94 patients were recruited for this study, 
according to inclusion and exclusion criterias. 
The characteristics of the patients in this study 





















•  75 










Hypertension 15 16% 
Diabetes Mellitus 20 21% 
Dyslipidemia 4 4.2% 





The cross tabulation data is shown on Table 2. 
  








Men 32 42 74 
0.795 Woman 8 12 20 
Total 40 54 94 
 
The comparatively analysis between 
elderly and non-elderly patients for ischemic 
wvents was carried out. The cross tabulation is 
shwon on Table 3.  
 
Table 3: Relationship between Age and 








 75 2 3 5 
0.199 
65 - <75 9 10 19 
< 65 29 41 70 
Total 40 54 94 
 
The profile of dual antiplatelet therapy in patients 




Table 4 Relationship between DAPT and ischemic based on the duration of antiplatelet use 
DAPT Combination Ischemic Events No Ischemic Events P-value 
Asa 100 – Tic 90 
Short 2 5 
0,157 
Standar 14 7 
Asa 100 – Cpg 75 
Short 5 3 
0.199 Standar 9 18 
Long term 4 4 
Asa 80 – Cpg 75 
Short 0 15  
Standar 1 2 
Asa 80 – Tic 90 
Short 1 0  
Standar 1 0 
Cpg 75 
Short 2 0  
Long term 1 0 
Short: 0-6 months; Standar: 7-12 months; Long term: >12 months 
Asa: asetylsalicylic acid; cpg: clopidogrel; tic: ticagrelor 
 
DISCUSSION 
From the characteristics of patients 
above at table 1, the number of female is less than 
male. It is suitable with the previous study which 
stated woman have an increasing cardiovascular 
risk in post menopause age. The risk is lower 
than man in the same age before menopause age. 
Estrogen take place in atherosclerosis process in 
woman, especially in metabolic factors such as 
lipid, inflammatory marker, and coagulation 
system. (Maas; Appelman, 2010). Based on that 
theory, the difference between male and female 
patients according to ischemic events was 
analysed. The cross tabulation data is shown on 
Table 2. Based on p-value in table 2, it was 
observed that there was no difference in ischemic 
events between both male and female patients. 
The results were conflicting with the result from 
previous study. Certain confusing factors such as 
the number of patients, compelling indications, 
and current drug use influences the results. 
As age increases, patients are at greater 
risk of experiencing cardiovascular event. This 
has been proven based on research conducted by 
Tsang et al, 2003 in which patients aged 70-74 
years and above are at high risk of cardiovascular 
events as measured by the Risk-Scoring 
Algorithm. One of the cardiovascular risk factors 
that cannot be changed is age. This age factor is 
often use in various calculations for 
cardiovascular risk events such as the 
Framingham Risk Score and SCORE issued by 
the European Society of Cardiology. 
Furthermore, age can also affect the reactivity of 
platelet in the body. This event is possible 
because the platelet reactivity is higher older 
patients. Theoretically, platelet reactivity is the 
tendency for hyperactivation, and can be 
determined when antiplatelet therapy didn’t 
show optimal effects (Nusca et al, 2012). 
The comparatively analysis between 
elderly and non-elderly patients for ischemic 
wvents was carried out. The cross tabulation is 
shwon on Table 3. From the p-value at table 3, it 
was concluded that there was no difference in 
ischemic events between elderly and non-elderly 
patients. Another study conducted by Verdoia et 
al, 2010, reported that patients aged> 70 years 
were more likely to experience High Residual on 
Treatment Platelet Reactivity (HRPR) on the use 
of antiplatelet agents. This is according to 
research conducted by Beltrame. F, John. What 
is the age of the most experienced CHD between 
50 and 65 years (Beltrame et al., 2012). This may 
be because the incidence of angina also increases 
with age.  In addition to the fact that aging also 
leads to a decrease in elasticity of the arterial 
wall, which prevents the arteries from expanding 
properly, which increases blood pressure and 
when there is infiltration of fat and cholesterol in 
the arteries, it become atherosclerosis and 
increases cardiovascular events. (Potter and 
Perry, 2005).  The results showed no difference 
in ischemic events between different age groups 
of patients. These results indicate a difference 
with the results of previous studies and many 
factors influence the differences in the results of 
this study, which includes the small number of 
study samples and other factors such as 
comorbidities, other cardiovascular risk factors, 
and the drugs used. 
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Patients undergoing percutaneous 
coronary intervention, received dual antiplatelet 
therapy. The duration of dual anti platelet therapy 
are categorized into several groups, such as short 
duration (0-6 months), standard (7-12 months), 
and long term (> 12 months). Some guidelines 
recommend using DAPT for 12 months provided 
the patient has no risk of bleeding. The duration 
is shortened when the patient experiences 
bleeding. The profile of dual antiplatelet therapy 
in patients is shown on Table 4.  
From the table 4 above, it can be seen 
that the combination of 100 mg aspirin and 75 
mg clopidogrel is most commonly used to treat 
double platelets. The combination of Aspirin and 
P2Y12 Inhibtor is recommended by the ESC 
Guideline for Dual Antiplatelet Therapy 
(DAPT). DAPT is recommended in some 
patients, such as Acute Coronary Syndromes 
(ACS) or patients with PCI (Valgimigli,2017). 
Low-dose Aspirin (80 mg) combined with 
Clopidogrel 75 mg is the second highest number 
of patient in this study. Aspirin act as antiplatelet 
by inhibit cyclo-oxygenase 1 enzyme and 
thromboxane production from the low dose 30-
50 mg. (Montalescot, 1991; Patrono, 1985). The 
range of antiplatelet doses are 75-100 mg for 
Aspirin, therefore, there was no differences 
between dose options.  
Based on the results of statistical 
analysis, there was no differences in ischemic 
events between the different duration groups of 
DAPT use. This is caused by the influence of 
other drugs combination used by patients. The 
major benefit of DAPT is the reduction of stent 
thrombosis event. The duration of DAPT 
treatment is recommended within 1 year, which 
is related to balance between the risk of ischemic 
and bleeding. DAPT treatment beyond 1 year in 
patients undergoing PCI or after Myocardial 
Infarction (MI), exerts most of its benefit to 
reduce spontaneous MI (Montalescot, 2017). 
Furthermore, there was a small number of patient 
that continue their DAPT over 1 year. Clinicians 
calculated the risks between ischemic and 
bleeding before making a decision to continue 
DAPT over 1 year. Some validated risk scores 
were validated for decision making during 
antiplatelet therapy duration, such as: PRECISE-
DAPT score (Costa, 2017) and DAPT Score 
(Yeh, 2016).  
The duration of the use of Dual 
Antiplatelet Therapy (DAPT) according to ESC 
Focused update on dual antiplatelet therapy in 
coronary artery disease developed in collaboratin 
EACTS in 2017 is divided into 3 types, such 
as short DAPT, which is 3-6 
months, standard/long DAPT for 12 - 24 months, 
and long DAPT for 30 months. This duration 
affect the incidence of cardiac death, MI, 
or ischemic after PCI. According to PCI, the use 
of DAPT is therefore a standard care. In post-PCI 
CHD patients with a diagnosis of stable CAD, 
when the patient has a small bleeding risk, a 
combination of aspirin-clopidogrel DAPT are 
used for 6 months. However, when the patient 
has a higher risk of bleeding, the combination of 
DAPT that are used is aspirin-clopidogrel for 1 
to 3 months. In post-PCI CHD patients 
diagnosed with ACS both NSTEMI and STEMI, 
when the patient has a small risk of bleeding the 
combination of DAPT that are used is aspirin-
ticagrelor or clopidogrel aspirin for 12 
months. Whereas patients with a high risk of 
bleeding uses a combination of DAPT aspirin-
clopidogrel or aspirin-ticagrelor for 6 
months. (Valgimigli et al, 2017 ). 
 
CONCLUSIONS  
There was no difference between both 
sex and age group with ischemic events. The 
most commonly use of dual antiplatelet therapy 
was aspirin-clopidogrel and aspirin-ticagrelor. 
There was no statistically significant difference 
between the duration of dual antiplatelet therapy 
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